Synergy Pharmaceuticals (SGYP) Downgraded by BidaskClub

Synergy Pharmaceuticals (NASDAQ:SGYP) was downgraded by stock analysts at BidaskClub from a “sell” rating to a “strong sell” rating in a report released on Tuesday, February 6th.

A number of other equities research analysts have also issued reports on the company. Cantor Fitzgerald reissued a “buy” rating and set a $10.00 price target on shares of Synergy Pharmaceuticals in a research note on Thursday, January 25th. Citigroup downgraded Synergy Pharmaceuticals to a “market perform” rating in a report on Friday, January 5th. Canaccord Genuity set a $13.00 price objective on Synergy Pharmaceuticals and gave the stock a “buy” rating in a report on Sunday, November 12th. Oppenheimer reiterated a “market perform” rating and issued a $10.00 price target on shares of Synergy Pharmaceuticals in a report on Friday, January 5th. Finally, HC Wainwright set a $7.00 price target on Synergy Pharmaceuticals and gave the company a “buy” rating in a report on Monday, December 4th. Two investment analysts have rated the stock with a sell rating, three have issued a hold rating and seven have issued a buy rating to the company’s stock. Synergy Pharmaceuticals currently has a consensus rating of “Hold” and an average target price of $8.28.

Shares of Synergy Pharmaceuticals (NASDAQ SGYP) opened at $2.05 on Tuesday. Synergy Pharmaceuticals has a one year low of $1.68 and a one year high of $6.45. The company has a quick ratio of 3.88, a current ratio of 4.26 and a debt-to-equity ratio of -68.13. The stock has a market capitalization of $505.65, a P/E ratio of -1.77 and a beta of 1.13.

A number of institutional investors and hedge funds have recently modified their holdings of the business. California State Teachers Retirement System lifted its position in Synergy Pharmaceuticals by 0.9% during the 2nd quarter. California State Teachers Retirement System now owns 401,730 shares of the biopharmaceutical company’s stock worth $1,788,000 after acquiring an additional 3,686 shares during the period. Raymond James Financial Services Advisors Inc. lifted its holdings in shares of Synergy Pharmaceuticals by 13.9% in the 2nd quarter. Raymond James Financial Services Advisors Inc. now owns 32,018 shares of the biopharmaceutical company’s stock valued at $142,000 after buying an additional 3,900 shares during the period. Amalgamated Bank lifted its holdings in shares of Synergy Pharmaceuticals by 16.9% in the 2nd quarter. Amalgamated Bank now owns 28,074 shares of the biopharmaceutical company’s stock valued at $125,000 after buying an additional 4,061 shares during the period. Principal Financial Group Inc. lifted its holdings in shares of Synergy Pharmaceuticals by 11.2% in the 2nd quarter. Principal Financial Group Inc. now owns 41,507 shares of the biopharmaceutical company’s stock valued at $185,000 after buying an additional 4,164 shares during the period. Finally, Advisor Group Inc. lifted its holdings in shares of Synergy Pharmaceuticals by 25.2% in the 2nd quarter. Advisor Group Inc. now owns 25,625 shares of the biopharmaceutical company’s stock valued at $114,000 after buying an additional 5,150 shares during the period. 60.68% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: “Synergy Pharmaceuticals (SGYP) Downgraded by BidaskClub” was originally published by Week Herald and is owned by of Week Herald. If you are accessing this report on another publication, it was illegally stolen and republished in violation of United States and international trademark and copyright legislation. The correct version of this report can be viewed at https://weekherald.com/2018/02/15/synergy-pharmaceuticals-sgyp-stock-rating-lowered-by-bidaskclub.html.

Synergy Pharmaceuticals Company Profile

Synergy Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of gastrointestinal (GI) therapies. The Company’s product candidates include TRULANCE (plecanatide) and dolcanatide. The Company is engaged in the discovery, research and development efforts around analogs of uroguanylin for the treatment of GI diseases and disorders.

Analyst Recommendations for Synergy Pharmaceuticals (NASDAQ:SGYP)

Receive News & Ratings for Synergy Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synergy Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply